Incidence of cancer in people living with HIV and prognostic value of current CD4+ - 04/03/19
, Luc-Aimé Kagoué Simeni 1, Gregoire Mbassa Nnouma 1, Mouhamadou Lawan Loubou 3, Idrissa Abamé 1, Aurelie Tchuisseu Hapi 1, Sabine Dooh Ngalle 1, Sorelle Hemerode Mbock 1, Mireille Mpondi Ngole Etame 4, Etienne Atenguena Okobalemba 5Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
Although Sub-Saharan Africa accounts for 71% of the people living with Human Immunodeficiency Virus (HIV) worldwide and Cameroon accounts for about 2% of them, the role of HIV-induced immunodeficiency and exposure to Antiretroviral Therapy (ART) in the occurrence of cancers in Cameroon has scarcely been examined. The aim of our study was to determine the incidence of cancers in HIV patients and to determine the role of CD4+cell count in the onset of cancers.
Methods |
A retrospective cohort study was carried out from medical records of people confirmed to be HIV-positive from 01 July 2003 to 30 April 2013. Potential risk factors were studied by Cox proportional hazards model.
Results |
A total of 1768 patients were included in the analysis and 53 cases of cancer were diagnosed with an incidence rate of 7.4 per 1000 person-year of follow-up (95% CI; 5.4–9.4 per 1000 person-years of follow-up). Immunosuppression and exposure to ART were identified as factors associated with the occurrence of cancers in this population. Current CD4+cell count was the most important risk factor for cancer. Risk of cancer ranged from 15.51 (95% CI; 5.45–44.1; P<0.001) for a CD4+ cell count<50 cells/mm3 to 2.87 (95% CI; 1.14–7.2; P=0.025) for a CD4+ level between 350–499 cells/mm3.
Conclusion |
Our study showed that the incidence rate of cancers is high among HIV patients in Cameroon. This incidence seems to correlate positively with the latest CD4+cell count and negatively with initiation of antiretroviral treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Cancer, HIV, Immunosuppression, CD4+cell count, Antiretroviral therapy
Plan
Vol 106 - N° 3
P. 201-205 - mars 2019 Retour au numéro
Article précédent
- Utilisation des médecines complémentaires et alternatives chez l’enfant et l’adolescent atteint de cancer : une pratique fréquente
- Vanessa Menut, Etienne Seigneur, Christèle Gras Leguen, Daniel Orbach, Estelle Thebaud
- Expérience du blinatumomab dans les leucémies aiguës lymphoblastiques de l’enfant et de l’adolescent dans l’interrégion Grand Ouest : une chance pour tous
- Margaux Camuset, Audrey Grain, Fleur Lorton, Odile Minckes, Anne Jourdain, Frédéric Millot, Isabelle Pellier, Virginie Gandemer, Fanny Rialland Battisti
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?